As per the agreement, Alexion will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of LogicBio for $2.07 per share, a rare 660% premium on LogicBio’s share price.

I n a notable market movement, shares of LogicBio Therapeutics, Inc. (LOGC) reached a 52-week high, trading at $8.24, marking a significant milestone after posting impressive gains of nearly 49% ...

His experience also includes M&A and corporate development at LogicBio Therapeutics ... creating a robust pipeline targeting CNS, neuromuscular and eye diseases. Headquartered in Paris, France ...